The global organs-on-chips market size is expected to reach USD 209.4 Million at a steady CAGR of 28.1% in 2028, according to latest analysis by Emergen Research. Steady market revenue growth can be attributed to growing demand for organs-on-chips for drug development and screening to reduce monetary losses associated with drug failures. The cost-effectiveness, miniaturized scale, and accurate control of organs-on-chips over the mechanical and chemical microenvironment are garnering significant traction across pharmaceutical and biotechnology companies to reduce rate of drug failure. Currently, two-dimensional novel drugs screening and in-vitro pharmacokinetics and pharmacodynamics analysis are prevalent practices before a drug can be sent to the next phase, such as preclinical testing phase. However, human body organs are three-dimensional entities and their intricate behavior cannot be effectively modeled in two-dimensional cultures. Use of organs-on-chips provide a microenvironment that mimics the pathophysiological conditions of the human body and thus, helps in saving substantial financial losses by substituting the trial and error method with a more reliable and efficient process. Read More@